ZIM Laboratories Limited (BOM:541400)

India flag India · Delayed Price · Currency is INR
75.64
-0.99 (-1.29%)
At close: Feb 12, 2026
Market Cap3.69B -25.3%
Revenue (ttm)3.78B -2.7%
Net Income69.83M -54.6%
EPS1.43 -54.4%
Shares Out48.74M
PE Ratio52.73
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,343
Average Volume5,316
Open77.37
Previous Close76.63
Day's Range74.10 - 77.49
52-Week Range64.10 - 126.95
Beta0.41
RSI54.85
Earnings DateFeb 11, 2026

About ZIM Laboratories

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and ... [Read more]

Industry Pharmaceutical Preparations
Founded 1984
Employees 577
Stock Exchange Bombay Stock Exchange
Ticker Symbol 541400
Full Company Profile

Financial Performance

In fiscal year 2025, ZIM Laboratories's revenue was 3.79 billion, an increase of 3.16% compared to the previous year's 3.68 billion. Earnings were 121.65 million, a decrease of -29.46%.

Financial Statements

News

Why ZIM Laboratories has received CDSCO approval for its new Naproxen + Esomeprazole capsules

ZIM Laboratories Limited has announced that it has secured approval from the Central Drugs Standard Control Organization (CDSCO) for its...

2 months ago - Business Upturn

ZIM Laboratories secures marketing authorization in Australia for urology drug combination

ZIM Laboratories Limited has received marketing authorization from Australia’s Therapeutic Goods Administration (TGA) for its fixed-dose combination capsules of Tamsulosin Hydrochloride and Dutasterid...

6 months ago - Business Upturn

ZIM Laboratories shares in focus as company gets first marketing approval in Australia

ZIM Laboratories Limited announced that it has secured its first Marketing Authorization (MA) in Australia for its Central Nervous System (CNS) drug, Rizatriptan Benzoate Orally Disintegrating Films, ...

7 months ago - Business Upturn